



UW Veterinary Care
UNIVERSITY OF WISCONSIN-MADISON

LOOKING FOR

Dogs with Anal Sac Adenocarcinoma

Clinical Assessment of Hypofractionated Radiotherapy on Anal Sac Adenocarcinoma

The Study

Anal sac adenocarcinoma can cause life-threatening symptoms at the site of the primary tumor, as well as at sites of metastasis (spread of cancer to a different location in the body). Treatment for this type of tumor is challenging, often involving surgery, radiation therapy, and chemotherapy. The goal of this study is to evaluate the benefits and safety of hypofractionated radiation therapy, which may change the way anal sac adenocarcinoma is treated in dogs.

Who Qualifies

Dogs with a measurable tumor diagnosed as anal sac adenocarcinoma that have not received any prior radiation therapy and are not currently receiving chemotherapy.

What Happens

Dogs will undergo a radiation treatment plan over three consecutive days on an out-patient basis. Patients will be evaluated 2 weeks post treatment, every 3 months for 1 year, and then every 6 months thereafter.

Owners will be asked to complete questionnaires throughout the duration of the study.

Why Participate

The study will allow us to evaluate the effect and tolerability of hypofractionated radiotherapy on this type of tumor. Recheck physical exams, as well as CT scans performed 3 months and 6 months after treatment will be paid for by the study.

More Information

Please contact Dr. Nate Van Asselt at nvanasselt@wisc.edu or Amy Wiltzius Elbe, CVT, LAT at awiltzius@wisc.edu or 608-890-3484, if you have questions or would like to participate.

